尺素金声｜对外授权超1300亿美元！我国新药全球“破圈”

Core Insights - The total transaction amount for new drug licensing has exceeded $130 billion, with the number of transactions surpassing 150, both reaching historical highs [1] - A total of 76 new drugs were approved for market launch, significantly exceeding the 48 approved in 2024, marking a historical peak [1] Industry Growth - The approval of first-class new drugs in China has increased significantly from 2018 to 2024, with 48 approved in 2024, over five times the number in 2018 [3] - Domestic drugs accounted for over 85% of the 76 new drugs approved in 2025, indicating a shift towards domestic innovation [3] - Among the newly approved drugs, 11 are globally innovative, with 4 developed independently in China, showcasing substantial progress in original innovation capabilities [3] Patient Impact - The acceleration of new drug innovation means more patients will receive effective treatments, enhancing public health security [4] - The approval of innovative drugs during the 14th Five-Year Plan period is expected to reach around 220, addressing major diseases and improving patient outcomes [4] Corporate Development - Jiangsu Hengrui Medicine exemplifies the success of increased investment in new drug innovation, with R&D expenditure rising from approximately 19% of revenue in 2015 to about 30% in 2024 [5] - The company has developed 24 first-class new drugs and 5 second-class new drugs, maintaining a position among the top 50 global pharmaceutical companies for seven consecutive years [5] - The large patient population in China allows companies to quickly realize substantial returns on successful drug development [5] Regulatory Environment - The reform of drug review and approval systems has significantly shortened the average review time from 14 months to 30 days, enhancing the efficiency of new drug approvals [6] - The Chinese government has implemented various supportive policies to foster new drug innovation, contributing to the rapid development of the pharmaceutical industry [6] - The ongoing reforms and supportive measures are expected to usher in a golden era for new drug innovation in China [6]